Advances in metered dose inhaler technology

Formulation development

Paul B Myrdal, Poonam Sheth, Stephen W. Stein

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.

Original languageEnglish (US)
Pages (from-to)434-455
Number of pages22
JournalAAPS PharmSciTech
Volume15
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Metered Dose Inhalers
Excipients
Technology
dosage
drugs
HFA 134a
Pharmaceutical Preparations
respiratory tract diseases
Suspensions
chlorofluorocarbons
Chlorofluorocarbons
bulking agents
asthma
Surface-Active Agents
surfactants
Chronic Obstructive Pulmonary Disease
Lung Diseases
droplets
polymers
Polymers

Keywords

  • ethanol
  • formulation
  • metered dose inhaler (MDI)
  • propellant
  • solubilization aids
  • suspending agents

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

Advances in metered dose inhaler technology : Formulation development. / Myrdal, Paul B; Sheth, Poonam; Stein, Stephen W.

In: AAPS PharmSciTech, Vol. 15, No. 2, 2014, p. 434-455.

Research output: Contribution to journalArticle

Myrdal, Paul B ; Sheth, Poonam ; Stein, Stephen W. / Advances in metered dose inhaler technology : Formulation development. In: AAPS PharmSciTech. 2014 ; Vol. 15, No. 2. pp. 434-455.
@article{c9f69d8a5684422e9063bdce5a6cad92,
title = "Advances in metered dose inhaler technology: Formulation development",
abstract = "Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.",
keywords = "ethanol, formulation, metered dose inhaler (MDI), propellant, solubilization aids, suspending agents",
author = "Myrdal, {Paul B} and Poonam Sheth and Stein, {Stephen W.}",
year = "2014",
doi = "10.1208/s12249-013-0063-x",
language = "English (US)",
volume = "15",
pages = "434--455",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "American Association of Pharmaceutical Scientists",
number = "2",

}

TY - JOUR

T1 - Advances in metered dose inhaler technology

T2 - Formulation development

AU - Myrdal, Paul B

AU - Sheth, Poonam

AU - Stein, Stephen W.

PY - 2014

Y1 - 2014

N2 - Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.

AB - Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.

KW - ethanol

KW - formulation

KW - metered dose inhaler (MDI)

KW - propellant

KW - solubilization aids

KW - suspending agents

UR - http://www.scopus.com/inward/record.url?scp=84898037878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898037878&partnerID=8YFLogxK

U2 - 10.1208/s12249-013-0063-x

DO - 10.1208/s12249-013-0063-x

M3 - Article

VL - 15

SP - 434

EP - 455

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 2

ER -